There has been continued focus today in the healthcare news media, on health blogs and Twitter on the US Senate Finance Committee's report regarding GSK and our diabetes medicine Avandia. Patients, doctors, media and others are asking questions about our company and the safety of our medicine. Looking at a lot of the content and commentary, it is clear that many people are only getting part of the story--or worse, the wrong message entirely.
In particular, misleading headlines stating that "FDA Report Advises Avandia be Pulled from the Market," were re-Tweeted dozens of times; other commentary we found to be more balanced including this piece in Forbes gained less attention. According to their own statement this afternoon, "FDA is now reviewing the primary data from the completed RECORD study, conducting follow-up audits, and reviewing additional studies. This work is ongoing and no new conclusions or recommendations about the use of rosiglitazone in the treatment of type 2 diabetes have been made at this time." FDA further advised doctors:
When prescribing rosiglitazone, healthcare professionals should follow the recommendations in the drug label. Patients should continue taking rosiglitazone unless told by their healthcare professional to stop. Patients who are concerned about the possible risks associated with using rosiglitazone should talk to their healthcare professional.
FDA has called for a public advisory panel meeting this July and we look forward to working with FDA and the panel to provide any further information they request.
We will continue to post new information and clarifications regarding this issue as we believe necessary, but hope to get back to using this space to focus on "More than Medicine."